About Exogene

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster an

Company Highlights
Year Founded

2019

icon-altEmployees

14

Location (HQ)

GBR

Since Last Funding

2 years 4 months

Monthly Website Visitors

5.2K

icon-altTotal Investment Amt

$2.1M

Last Funding Round

Seed

icon-altYoY Headcount Growth

39.6%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology

Biotechnology Research

Pharmaceutical

Life Science